MCID: PNC006
MIFTS: 39

Pancreatic Somatostatinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Somatostatinoma

MalaCards integrated aliases for Pancreatic Somatostatinoma:

Name: Pancreatic Somatostatinoma 37 12 14 69
Pancreatic Delta Cell Somatostatin Producing Neoplasm 12
Pancreatic Somatostatin Cell Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4432
NCIt 46 C8006 C95595
UMLS 69 C1368041

Summaries for Pancreatic Somatostatinoma

MalaCards based summary : Pancreatic Somatostatinoma, also known as pancreatic delta cell somatostatin producing neoplasm, is related to somatostatinoma and duodenal somatostatinoma, and has symptoms including diarrhea An important gene associated with Pancreatic Somatostatinoma is SST (Somatostatin), and among its related pathways/superpathways is Neuroscience. The drugs Pancreatic Polypeptide and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, liver and breast.

Related Diseases for Pancreatic Somatostatinoma

Diseases related to Pancreatic Somatostatinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 168)
# Related Disease Score Top Affiliating Genes
1 somatostatinoma 31.9 CALCA ENO2 SST
2 duodenal somatostatinoma 28.7 CALCA ENO2 PPY SST
3 pancreatitis 10.5
4 wdha syndrome 10.4 CALCA SST
5 prolactin producing pituitary tumor 10.3 CALCA SST
6 vipoma 10.3 CALCA SST
7 hormone producing pituitary cancer 10.3 MEN1 SST
8 retinitis pigmentosa 40 10.3 PPY SST
9 functioning pituitary adenoma 10.3 MEN1 SST
10 zollinger-ellison syndrome 10.3 MEN1 SST
11 gastrinoma 10.2 MEN1 SST
12 multiple endocrine neoplasia, type iib 10.2 CALCA MEN1
13 malignant glandular tumor of peripheral nerve sheath 10.2 SST SYP
14 adenoma of the pancreas 10.2 SST SYP
15 fibrous dysplasia 10.2 CALCA SST
16 pancreatic endocrine carcinoma 10.2 SST SYP
17 endocrine pancreas disease 10.2 PPY SST
18 endocrine organ benign neoplasm 10.2 MEN1 SST
19 duodenal gastrinoma 10.2 MEN1 PPY
20 pancreatoblastoma 10.2 SST SYP
21 pituitary tumors 10.2 MEN1 SST
22 serotonin syndrome 10.2 MEN1 SST
23 parathyroid gland disease 10.2 CALCA MEN1
24 functional colonic disease 10.2 SST SYP
25 binswanger's disease 10.2 SST SYP
26 pancreas disease 10.2 PPY SST
27 parathyroid carcinoma 10.2 CALCA MEN1
28 multiple endocrine neoplasia, type iia 10.2 CALCA MEN1
29 hyperinsulinemic hypoglycemia 10.2 MEN1 SST
30 pituitary gland disease 10.1 MEN1 SST
31 colonic pseudo-obstruction 10.1 SST SYP
32 pancreatic cystadenocarcinoma 10.1 CALCA SYP
33 multiple endocrine neoplasia 10.1 CALCA MEN1
34 tanycytic ependymoma 10.1 MEN1 SYP
35 non-functioning pancreatic endocrine tumor 10.1 PPY SYP
36 pituitary adenoma, prolactin-secreting 10.1 MEN1 SST
37 retroperitoneal neuroblastoma 10.1 ENO2 SST
38 parathyroid adenoma 10.1 CALCA MEN1
39 acute thyroiditis 10.0 CALCA ENO2
40 pituitary adenoma 10.0 MEN1 SST
41 neurofibromatosis, type iv, of riccardi 10.0 MEN1 SST
42 small intestine cancer 10.0 ENO2 SST
43 diffuse pulmonary fibrosis 10.0 CALCA ENO2
44 cloacogenic carcinoma 10.0 CALCA ENO2
45 pancreatic islet cell tumors 10.0 CALCA MEN1 SST
46 islet cell tumor 10.0 CALCA MEN1 SST
47 chondroid lipoma 10.0 ENO2 MEN1
48 thyroid cancer, nonmedullary, 2 10.0 CALCA MEN1 SST
49 acromegaly 9.9 MEN1 SST
50 hypoglycemia 9.9

Graphical network of the top 20 diseases related to Pancreatic Somatostatinoma:



Diseases related to Pancreatic Somatostatinoma

Symptoms & Phenotypes for Pancreatic Somatostatinoma

UMLS symptoms related to Pancreatic Somatostatinoma:


diarrhea

Drugs & Therapeutics for Pancreatic Somatostatinoma

Drugs for Pancreatic Somatostatinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
5
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
6
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
9
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
10 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
11 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
12 Antimetabolites Phase 2, Phase 3,Phase 1
13 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
14 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
15 Adjuvants, Anesthesia Phase 3
16 Analgesics Phase 3
17 Analgesics, Opioid Phase 3
18 Anesthetics Phase 3
19 Anesthetics, General Phase 3
20 Anesthetics, Intravenous Phase 3
21 Central Nervous System Depressants Phase 3
22 Narcotics Phase 3
23 Peripheral Nervous System Agents Phase 3
24 Folate Nutraceutical Phase 2, Phase 3
25 Vitamin B9 Nutraceutical Phase 2, Phase 3
26 Cola Nutraceutical Phase 3,Phase 2,Phase 1
27
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
28
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
29
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
30
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
31
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
32
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
33
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
34
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
35
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
36
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
37
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
38
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 6400441 383414
39
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
40
Pancrelipase Approved, Investigational Phase 2 53608-75-6
41
Melphalan Approved Phase 2 148-82-3 460612 4053
42
Somatostatin Approved, Investigational Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
43
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
44
Gemcitabine Approved Phase 2 95058-81-4 60750
45
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
46
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
47
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4 445354
49
Vatalanib Investigational Phase 2,Phase 1 212141-54-3 151194
50 Anti-Bacterial Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 35)

# Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
5 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
6 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
7 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
8 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
9 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
10 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
11 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
12 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
13 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
14 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
15 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
16 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
17 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
18 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
19 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
20 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
21 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Terminated NCT01056601 Phase 2 Bortezomib;Panobinostat
22 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
23 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
24 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
25 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
26 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
27 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
28 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
29 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
30 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
31 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
32 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
33 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
34 Ga-DOTATOC Versus Octreoscan + CT Suspended NCT01869725
35 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Terminated NCT00730483 PVA microporous hydrospheres/doxorubicin hydrochloride

Search NIH Clinical Center for Pancreatic Somatostatinoma

Genetic Tests for Pancreatic Somatostatinoma

Anatomical Context for Pancreatic Somatostatinoma

MalaCards organs/tissues related to Pancreatic Somatostatinoma:

38
Liver, Breast, Endothelial, Pancreas, Bone, Kidney, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Somatostatinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Delta Cells Affected by disease

Publications for Pancreatic Somatostatinoma

Articles related to Pancreatic Somatostatinoma:

(show all 30)
# Title Authors Year
1
Pancreatic somatostatinoma diagnosed preoperatively: report of a case. ( 24413789 )
2014
2
Cardiac metastasis from malignant pancreatic somatostatinoma. ( 19733881 )
2010
3
Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern. ( 20043348 )
2010
4
FNAC diagnosis of pancreatic somatostatinoma. ( 21938182 )
2009
5
Pancreatic somatostatinoma and tuberous sclerosis: case report of an exceedingly rare association. ( 18672238 )
2009
6
Pancreatic somatostatinoma manifested as severe hypoglycemia. ( 19565056 )
2009
7
Pancreatic somatostatinoma characterized by extreme hypoglycemia. ( 19719976 )
2009
8
Pancreatic somatostatinoma with von Recklinghausen's disease. ( 18926936 )
2009
9
Diagnosis and treatment of pancreatic somatostatinoma: a case report. ( 19080351 )
2008
10
Fine-needle aspiration cytology of pancreatic somatostatinoma: the importance of immunohistochemistry for the cytologic diagnosis of pancreatic endocrine neoplasms. ( 16007666 )
2005
11
A small, incidentally detected pancreatic somatostatinoma: report of a case. ( 12560911 )
2003
12
Periampullary pancreatic somatostatinoma. ( 12417508 )
2002
13
Calcitonin-producing pancreatic somatostatinoma: report of a case. ( 9872549 )
1998
14
Reciprocal changes in progression of gastric mucosa-associated lymphoid tissue lymphoma and pancreatic somatostatinoma. ( 9870841 )
1998
15
Brain metastasis from malignant pancreatic somatostatinoma. Case report. ( 8814175 )
1996
16
Pancreatic somatostatinoma presenting with chronic intestinal pseudo-obstruction syndrome. ( 17912215 )
1996
17
Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. ( 7745981 )
1995
18
Pancreatic somatostatinoma: a case report and review of the literature. ( 1969977 )
1990
19
Pancreatic somatostatinoma. ( 2077482 )
1990
20
Pancreatic somatostatinoma: presentation with recurrent episodes of severe hyperglycaemia and ketoacidosis. ( 2855274 )
1988
21
Malignant pancreatic somatostatinoma in a patient with dermatitis herpetiformis and coeliac disease. ( 2899527 )
1988
22
Pancreatic somatostatinoma. ( 6314830 )
1983
23
Pancreatic somatostatinoma. ( 6314831 )
1983
24
Pancreatic somatostatinoma: abundance of somatostatin-28(1-12)-like immunoreactivity in tumor and plasma. ( 6137494 )
1983
25
Pancreatic somatostatinoma presenting with hypoglycaemia. ( 6105026 )
1980
26
Molecular forms of somatostatin in normal subjects and in patients with pancreatic somatostatinoma. ( 6105027 )
1980
27
Calcitonin-producing pancreatic somatostatinoma. ( 6102950 )
1980
28
Pancreatic somatostatinoma: histologic, clinical, and angiographic features. ( 227259 )
1979
29
Calcitonin secretion by a pancreatic somatostatinoma. ( 714084 )
1978
30
Pancreatic somatostatinoma. Clinical features and physiological implications. ( 66472 )
1977

Variations for Pancreatic Somatostatinoma

Expression for Pancreatic Somatostatinoma

Search GEO for disease gene expression data for Pancreatic Somatostatinoma.

Pathways for Pancreatic Somatostatinoma

Pathways related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.33 CALCA ENO2 SYP

GO Terms for Pancreatic Somatostatinoma

Cellular components related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 terminal bouton GO:0043195 8.96 CALCA SYP
2 neuronal cell body GO:0043025 8.8 CALCA ENO2 SST

Biological processes related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.5 CALCA PPY SST
2 digestion GO:0007586 9.26 PPY SST
3 response to heat GO:0009408 9.16 CALCA SST
4 feeding behavior GO:0007631 8.96 CALCA PPY
5 cell-cell signaling GO:0007267 8.8 CALCA PPY SST

Molecular functions related to Pancreatic Somatostatinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CALCA PPY SST

Sources for Pancreatic Somatostatinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....